XtalPi Inc. announced it has received $400 million (CNY 2.5918 billion) in its series D round of funding led by OrbiMed Advisors LLC and RRJ Capital on August 11, 2021. The transaction also included participation from Sino Biopharmaceutical Limited, Hopu Fund, a fund managed by HOPU Jinghua (Beijing) Investment Consultancy Co., Ltd., returning investors Sequoia China Investment Management LLP and 5Y Capital. The round was raised at a valuation of CNY 13 billion.